NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage global leader in antiviral nanomedicines, announced it has engaged Aagami, Inc. for business development. The collaboration targets licensing and partnership opportunities for NanoViricides' assets and platform technology in India and Japan.

With NV-387 as its key asset, NanoViricides has completed a Phase I clinical trial in India, revealing no adverse events even at high doses. NV-387, designed as an ultra-broad-spectrum antiviral nanomedicine, is now set for Phase II clinical trials.

Aagami Inc. will focus on licensing and partnership opportunities to advance NV-387's development. The partnership is expected to free up NanoViricides' executive team to concentrate on further drug development and clinical trials.

NV-387 targets multiple viruses, including SARS-CoV-2, RSV, and Influenza A. Its unique mechanism involves mimicking host-side features that remain constant despite viral mutations, providing a robust defense against virus escape.